Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

Al­most two years ago Pfiz­er and Mer­ck KGaA con­ced­ed that their PD-L1 drug failed to sig­nif­i­cant­ly im­prove over­all sur­vival for gas­tric can­cer pa­tients in the third-line set­ting. We now know that Baven­cio doesn’t work as a first-line main­te­nance ther­a­py, ei­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER